Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05344339
Other study ID # 15/GCN-HDDD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 8, 2022
Est. completion date April 30, 2025

Study information

Verified date December 2023
Source University Medical Center Ho Chi Minh City (UMC)
Contact Long D. Vo, MD PhD
Phone +84918133915
Email long.vd@umc.edu.vn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy. Hypothesis: Billroth-II modified method is non-inferior to Roux-en-Y method in terms of reducing reflux esophagitis after distal gastrectomy for gastric cancer patients.


Description:

Since the first gastrectomy by Theodore Billroth in 1881, this procedure remained a curative treatment for gastric cancer. Reconstruction method after gastrectomy may affect complication rates, post-operative nutritional status, and quality of life (QoL). There are several reconstruction methods for distal gastrectomy, including Billroth I (B-I), Billroth II (B-II), Roux-en-Y (R-Y). B-I and B-II were considered better than R-Y in terms of shorten operation time and lessen blood loss due to technical simplicity. In contrast, R-Y was better in terms of preventing bile reflux and remnant gastritis, which can increase remnant stomach cancer and worsen QoL. However, long term QoL was similar between B-I and R-Y in some randomized controlled trials. Although bile reflux was higher in B-I and B-II groups, remnant gastric cancer was similar between 3 groups in this study. In brief, which one is the ideal reconstruction after distal gastrectomy is still controversial. At our center, reconstruction after distal and sub-total gastrectomy including B-I, B-II, B-II with Braun anastomosis, and R-Y, depended mostly on surgeons' preferences. From 2018, to decrease bile reflux rate while not increasing operation time, we applied modified B-II technique with 3-5 sutures between the afferent loop to the gastric remnant. This study was conducted to evaluate the efficacy of this method by comparing it with the R-Y method.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date April 30, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients confirmed with gastric cancer - Indicated for radical distal gastrectomy (cT1 to cT4a, any N, M0; according to AJCC/UICC 8th TNM staging for gastric cancer) - Age from 18- to 80-year-old - Agreed to participate in study with written inform consent Exclusion Criteria: - Pregnant patients - An American Society of Anesthesiology (ASA) score of higher than 4 - Concurrent cancer or history of previous other cancers - Previous gastrectomy - Complications including bleeding, perforation required emergency gastrectomy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Distal gastrectomy
Reconstruction after Distal Gastrectomy

Locations

Country Name City State
Vietnam University Medical Center Ho Chi Minh City Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Ho Chi Minh City (UMC)

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reflux esophagistis Findings of reflux esophagitis according to Los Angeles classification via endoscopy on the 12th month after surgery
Secondary Early complications Rate of any complications happened intraoperative and 30-days post-operative 30 days after surgery
Secondary Operative time Time from first incision to finishing abdomen closure, measured by surgical nurse Intraoperative
Secondary Time for making anastomosis Time from jejunal stapler opening (for B-II) or from jejunal separating (for R-II) to finishing enhancing suture (including duodenal stump enhancement) Intraoperative
Secondary Blood loss Weighing of sucked blood and gauze, minus weighing of dry gauze Intraoperative
Secondary Length of post-operative hospital stay Number of days from date of surgery until date of discharge or mortality 30 days after surgery or until mortality
Secondary Post gastrectomy syndromes Rate of post gastrectomy syndromes after gastrectomy from 30 days to 1 years after surgery
Secondary Bodyweight Changing of patient's weight at the follow-up time compare to weight before surgery on the 3rd, 6th, and 12th month after surgery
Secondary Serum total protein Changing of patient's serum total protein at the follow-up time compare to serum protein before surgery on the 3rd, 6th, and 12th month after surgery
Secondary Serum albumin Changing of patient's serum albumin at the follow-up time compare to serum albumin before surgery on the 3rd, 6th, and 12th month after surgery
Secondary Hemoglobin Changing of patient's hemoglobin at the follow-up time compare to hemoglobin before surgery on the 3rd, 6th, and 12th month after surgery
Secondary Changing of Gastric remnant gastritis Grade of gastric remnant gastritis according to RGB classification (for endoscopy) and updated Sydney classification (for histology) on the 6th, and 12th month after surgery
Secondary Changing of Residual food Grade of Residual food according to RGB classification via endoscopy on the 6th, and 12th month after surgery
Secondary Changing of bile reflux Finding of bile reflux according to RGB classification via endoscopy on the 6th, and 12th month after surgery
Secondary Changing of GSRS score Patient's quality of life evaluated using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire on the 3rd, 6th, and 12th month after surgery
Secondary 6th month reflux esophagistis Findings of reflux esophagitis according to Los Angeles classification via endoscopy on the 6th month after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2